Primate models of Parkinson's disease

Experimental Neurology

Volumn 183, Issue 2, 2003, Pages 258-262

  Collier, Timothy J ^a   Steece Collier, Kathy ^a   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

AKINESIA; BRADYKINESIA; IDIOPATHIC DISEASE; IMMUNOREACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; NOTE; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; RIGIDITY; SUBSTANTIA NIGRA; SYMPTOM; TREMOR;

EID: 0141783954     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00246-2     Document Type: Note

References (59)

1. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman D.M., Jacobowitz D.M., Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39:1986;7-16.
2. Barbeau A. The use of L-dopa in Parkinson's disease a 20 year follow-up . Trends Pharmacol. Sci. 2:1981;297-299.
3. Baron M.S., Wichmann T., Ma D., DeLong M.R. Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J. Neurosci. 22:2002;592-599.
4. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine, and MPTP contribution to the apoptotic theory in Parkinson's disease . Prog. Neurobiol. 65:2001;135-172.
5. Brotchie J.M. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann. Neurol. 47:(Suppl. 1):2000;S105-S114.
6. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine . Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
7. Cenci M.A. Transcription factors involved in the pathogenesis of l-dopa-induced dyskinesias in a rat model of Parkinson's disease. Amino Acids. 23:2002;105-109.
8. Cenci M.A., Whishaw I.Q., Schallert T. Animals models of neurological deficits how relevant is the rat . Nat. Rev. Neurosci. 3:2002;574-579.
9. Collier, T.J., Daley, B.F., Gyawali, S., Lipton, J.W., Ling, Z.D., Carvey, P.M., Sortwell, C.E., Pitzer, M.R., McGuire, S.O., Fletcher-Turner, A., Yurek, D.M., Leventhal, L., Emborg, M.E., Blanchard, B., Steece-Collier, K., Palfi, S., Sladek Jr., J.R., Kordower, J.H., 2001. Aging and the response to mesostriatal dopamine system lesion in MPTP-treated monkeys. Soc. Neurosci. 27, Abstr. 749.4.
10. Costa S., Iravani M.M., Pearce R.K., Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur. J. Pharmacol. 412:2001;45-50.
11. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 122:1999;1437-1448.
12. Davis K.L., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1:1979;249-254.
13. Degryse A.D., Colpaert F.C. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey (Macaca cynomolgus fascicularis (Raffles)). Brain Res. Bull. 16:1986;561-571.
14. DiMonte D.A., Lavasani M., Manning-Bog A.B. Environmental factors in Parkinson's disease. Neurotoxicology. 23:2002;487-502.
15. Elsworth J.D., Deutch A.Y., Redmond D.E. Jr., Sladek J.R. Jr., Roth R.H. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Res. 415:1987;293-299.
16. Elsworth J.D., Deutch A.Y., Redmond D.E. Jr., Taylor J.R., Sladek J.R. Jr., Roth R.H. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates biochemical changes in striatal regions . Neuroscience. 33:1989;323-331.
17. Elsworth J.D., Taylor J.R., Sladek J.R. Jr., Collier T.J., Redmond D.E. Jr., Roth R.H. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience. 95:2000;399-408.
18. Eslamboli A., Baker H.F., Ridley R.M., Annett L.E. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys. Exp. Neurol. 183:2003;418-429.
19. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47:(Suppl. 1):2000;S2-S11.
20. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillin S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344:2001;710-719.
21. Gerhardt G.Z., Cass W.A., Yi A., Zhang Z., Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J. Neurochem. 80:2002;168-177.
22. German D.C., Dubach M., Askari S., Speciale S.G., Bowden D.M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in macaca fascicularis which midbrain dopaminergic neurons are lost . Neuroscience. 24:1988;161-174.
23. Gibb W.R.G., Lees A.R. The significance of the lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol. Appl. Neurobiol. 15:1989;27-44.
24. Glinka Y., Gassen M., Youdim M.B. Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm. Suppl. 50:1997;55-66.
25. Hagel P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., Crabb L., Pavese N., Oertel W.H., Quinn N., Brooks D.J., Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5:2002;627-628.
26. Hirsch E.C., Graybiel A.M., Agid Y. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. Acta Neurol. Scand. 126:1989;19-22.
27. Hornykiewicz O. The mechanism of action of L-dopa in Parkinson's disease. Life Sci. 15:1974;1249-1259.
28. Jankovic J., Marsden D. Therapeutic strategies in Parkinson's disease. Jankovic J., Tolosa E. Parkinson's Disease and Movement Disorders. 1998;191-220 Williams and Wilkins, Baltimore.
29. Jenner P., Rpuniak N.M.J., Rose S., Kelly E., Kilpatrick G., Lees A., Marsden C.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 50:1984;85-90.
30. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein a new primate model of Parkinson's disease . Proc. Natl. Acad. Sci. USA. 100:2003;2884-2889.
31. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with Parkinson's disease. N. Engl. J. Med. 318:1988;876-880.
32. Kitt C.A., Cork L.C., Eidelberg F., Joh T.H., Price D.L. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine a tyrosine hydroxylase immunocytochemical study in monkey . Neuroscience. 17:1986;1089-1103.
33. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54:2000;1589-1595.
34. Kordower J.H., Emborg M.E., block J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitbewrg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
35. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 11:2000;211-213.
36. Langston J.W., Ballard P.A., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
37. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292:1984;390-394.
38. Langston J.W., Quik M., Petzinger G., Jakowec M., DiMonte D.A. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann. Neurol. 47:(Suppl. 1):2000;S79-S89.
39. Lee C.S., Cenci M.A., Schulzer M., Bjorklund A. Embyronic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain. 123:2000;1365-1379.
40. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15:2002;120-132.
41. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., Breeze R., Fahn S., Freed C., Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism a PET study . Ann. Neurol. 52:2002;628-634.
42. Mayeux R., Marder K., Cote L.J., Denaro J., Hemenegildo N., Mejia H., Tang M.X., Lantigua R., wilder D., Gurland B. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am. J. Epidemiol. 142:1995;820-827.
43. Moussaoui S., Obinu M.C., Daniel N., Reibaud M., Blanchard V., Imperato A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 166:2000;235-245.
44. Ovadia A., Zhang Z., Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging. 16:1995;931-937.
45. Pearce R.K., Costa S., Jenner P., Marsden C.D. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets. J. Neural Transm. 106:1999;663-683.
46. Perry T.L., Yong V.W., Hansen S., Jones K., Bergeron C., Foulks J.G., Wright J.M. Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurol Sci. 81:1987;321-331.
47. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 13:(Suppl. 1):1998;35-38.
48. Rodriguez M.C., Guridi O.J., Alvarez L., Mewes K., Macias R., Vitek J., DeLong M.R., Obeso J.A. The subthalamic nucleus and tremor in Parkinson's disease. Mov. Disord. 13:(Suppl. 3):1998;111-118.
49. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine a combined retrograde tracing and immunocytochemical study in the rat . Neuroscience. 59:1994;401-415.
50. Schwartzman R.J., Guillermo M.A., Mamelo M. Changes in regional glucose metabolism in the mesocortical dopaminergic system of a primate model of Parkinson's disease. Neurology. 35:1985;116-121.
51. Sladek J.R. Jr., Collier T.J., Elsworth J.D., Roth R.H., Taylor J.R., Redmond D.E. Jr. Fetal grafts in Parkinson's disease. Primate models. Tuszynski M.H., Kordower J.H. CNS Regeneration. Basic Science and Clinical Advances. 1999;321-364 Academic Press, San Diego.
52. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Greenamyre J.T. Antiparkinsonian actions of CP-101,606, an antagonist of the NR2B subunit of the N-methyl-D-aspartate receptor in non-human primates. Exp. Neurol. 163:2000;239-243.
53. Stephans S.E., Miller G.W., Levey A.I., Greenamyre J.T. Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. Neurotoxicology. 23:2002;569-580.
54. Tanner C.M., Langston J.W. Do environmental toxins cause Parkinson's disease? A critical review. Neurology. 40:1990;17-30.
55. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R. Jr., Redmond D.E. Jr. Behavioral effects of MPTP administration in the vervet monkey a primate model of Parkinson's disease . Woodruff M.L., Nonneman A.J. Toxin-Induced Models of Neurological Disorders. 1994;139-174 Plenum, New York.
56. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R. Jr., Redmond D.E. Jr. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience. 81:1997;745-755.
57. Tetrud J.W., Langston J.W. MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurol. Scand. 126:1989;35-40.
58. Vingerhoets F.J.G., Snow B.J., Tetrud J.W., Langston J.W., Schulzer M., Calne D.B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. 36:1994;765-770.
59. 11C-CFT . Exp. Neurol. 126:1994;305-309.